vobramitamab duocarmazine + lorigerlimab

This is a **combination investigational therapy** comprising two agents: vobramitamab duocarmazine and lorigerlimab. - **Vobramitamab duocarmazine** is an antibody-drug conjugate (ADC) that targets B7-H3 (CD276 antigen) on tumor cells and delivers a duocarmycin-based DNA-alkylating cytotoxic payload via a cleavable peptide linker. It was primarily developed for solid tumors, including prostate cancer and small cell lung cancer, but clinical development in several indications has been discontinued[1][4][5][7][10]. - **Lorigerlimab** is a bispecific, Fc-bearing (IgG4) DART (Dual-Affinity Re-Targeting) molecule targeting PD-1 and CTLA-4 immune checkpoints. It is designed to enhance local immunomodulation by increasing CTLA-4 antagonism in the tumor microenvironment while minimizing peripheral toxicity. Lorigerlimab is in ongoing trials for advanced solid tumors, including ovarian cancer and castration-resistant prostate cancer[3][6][9]. The combination represents a strategy to target tumor cells directly by ADC-mediated cytotoxicity and to stimulate anti-tumor immune responses by dual immune checkpoint blockade.

Other names

vobra duo + lorigerlimabanti-B7-H3 antibody drug conjugate + lorigerlimab